Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Anacor Pharmaceuticals to Hold Conference Call Tomorrow, March 21, 2013 at 8am ET / 5am PT to Discuss Preliminary Results From the Phase 2 Dose-Ranging Study of AN2728 in the Treatment of Adolescents With Atopic Dermatitis

Anacor Pharmaceuticals
Posted on: 21 Mar 13

Anacor Pharmaceuticals (NASDAQ:ANAC) will release preliminary results from the Phase 2 dose-ranging study of AN2728 in the treatment of adolescents with atopic dermatitis tomorrow March 21 2013 at approximately 7:00 a.m. ET. The announcement will be followed by a conference call at 8:00 a.m. ET to discuss the results.

The call can be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and can be accessed on the Events and Presentations page under Investors on the company’s website at and will be available for three months following the call.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered eight compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — tavaborole an antifungal for the treatment of onychomycosis and AN2728 an anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898 which are backup compounds to tavaborole and AN2728 respectively and AN3365 (formerly referred to as GSK2251052 or GSK ‘052) an antibiotic for the treatment of infections caused by Gram-negative bacteria which previously was licensed to GlaxoSmithKline LLC or GSK. GSK has returned all rights to the compound to us and we are considering our options for further development if any of this compound. We have also discovered three other compounds that we have out-licensed for further development — two are licensed to Eli Lilly and Company for the treatment of animal health indications and the third compound AN5568 also referred to as SCYX-7158 is licensed to Drugs for Neglected Diseases initiative or DNDi for human African trypanosomiasis (HAT or sleeping sickness). We also have a pipeline of other internally discovered topical and systemic boron-based compounds in development. For more information visit

Business Wire

Last updated on: 21/03/2013

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.